Profit lagging revenue
Revenue grew 17.0% but profit declined 3.6%, so the company kept less of each rupee of revenue as profit.
Importance 69 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Revenue grew 17.0% but profit declined 3.6%, so the company kept less of each rupee of revenue as profit.
Importance 69 / 95 · growth
Revenue grew 17.0% but EBITDA margin fell 1.3 percentage points to 27.8%, so the company kept less of each rupee of revenue as operating profit.
Importance 60 / 95 · growth
ROE declined from 16.7% to 12.5% year on year.
Importance 44 / 95 · profitability
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 17.7% a year over 3 years, from ₹8,749 cr in FY2023 to ₹14,278 cr in FY2026. Net profit grew 14.0% a year over the same period.
Revenue grew 17.0% but profit declined 3.6%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Revenue grew 17.0% but EBITDA margin fell 1.3 percentage points to 27.8%, so the company kept less of each rupee of revenue as operating profit.
Revenue grew 17.0% year on year (FY2025 → FY2026).
In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,338 cr (up 17.3% on the same quarter last year) and net profit ₹716 cr (up 37.7%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹716 cr, up 37.7% from ₹520 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 EBIT was ₹1,030 cr, up 30.2% from ₹791 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
Q2 FY27 revenue was ₹4,338 cr, up 17.3% from ₹3,697 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 3,230 | +23.9% | 385 | −16.4% | 11.9% |
| Q4 FY25 | 3,079 | +26.1% | 425 | −10.9% | 13.8% |
| Q1 FY26 | 3,570 | +23.4% | 445 | −18.1% | 12.5% |
| Q2 FY26 | 3,697 | +20.2% | 520 | −21.1% | 14.1% |
| Q3 FY26 | 3,567 | +10.4% | 414 | +7.6% | 11.6% |
| Q4 FY26 | 3,443 | +11.8% | 559 | +31.7% | 16.2% |
| Q1 FY27 | 4,031 | +12.9% | 574 | +29.1% | 14.2% |
| Q2 FY27 | 4,338 | +17.3% | 716 | +37.7% | 16.5% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 27.8% in FY2026, against 23.2% in FY2023. ROE was 12.5% and ROCE 13.4% in FY2026.
ROE declined from 16.7% to 12.5% year on year.
Rule ROE_DETERIORATED_YOY
Debt-to-equity was 0.38x in FY2026, against 0.02x in FY2023; interest coverage 4.83x. Operating cash flow was 1.61x net profit.
Debt-to-equity fell from 0.58× to 0.38× year on year.
Rule LEVERAGE_DECREASED_YOY
Within its 12-company Pharmaceuticals peer group, it ranks 8 of 12 on return on equity and 7 of 12 on EBITDA margin. Its P/E of 48.5 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated). No peer-relative rule fired for this company.
MANKIND · 5th of 12 · set median 14.8%
MANKIND · 7th of 12 · set median 28.7%
MANKIND · 8th of 12 · set median 14.4%
MANKIND · 7th of 12 · set median 45.3×
On the trailing twelve months. Last full year: P/E 56.7× · P/S 7.5× · ROE 12.5%. TTM and full-year profit differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 18.8% over 1 year and up 36.6% over 3 years (11.0% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is at its 52-week high; price history covers less than 5 years.
Over 3 years profit (14.0% a year) and the stock (11.0% a year) compounded at roughly the same rate — the FY2023 base was somewhat depressed, so part of this is recovery rather than trend.
Rule STOCK_TRACKED_EARNINGS · rebound
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 8,749 | 10,335 | 12,207 | 14,278 |
| Total income | 8,878 | 10,616 | 12,744 | 14,636 |
| EBITDA | 2,029 | 2,816 | 3,555 | 3,976 |
| Profit before tax | 1,659 | 2,384 | 2,504 | 2,321 |
| Net profit | 1,310 | 1,942 | 2,011 | 1,938 |
| EPS (₹) | 32.0 | 47.8 | 49.3 | 46.4 |
| Net worth | 7,623 | 9,576 | 14,568 | 16,561 |
| Total debt | 170 | 207 | 8,511 | 6,312 |
| Operating cash flow | 1,813 | 2,152 | 2,413 | 3,121 |
| Free cash flow | 1,030 | 1,845 | 1,965 | 2,498 |
| Ratio | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Growth | ||||
| Revenue growth YoY | — | 18.1 | 18.1 | 17.0 |
| Profit growth YoY | — | 48.3 | 3.6 | -3.6 |
| Profitability | ||||
| EBITDA margin % | 23.2 | 27.2 | 29.1 | 27.8 |
| Net margin % | 14.8 | 18.3 | 15.8 | 13.2 |
| Return on equity % | 17.2 | 22.6 | 16.7 | 12.5 |
| Return on capital % | 21.9 | 27.5 | 17.9 | 13.4 |
| Leverage & cash | ||||
| Debt to equity | 0.02 | 0.02 | 0.58 | 0.38 |
| Cash flow ÷ profit | 1.38 | 1.11 | 1.20 | 1.61 |
| Current ratio | 2.38 | 3.14 | 1.27 | 1.10 |